Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio to Distribute BellBrook's Assay for Epigenetics Research

NEW YORK (GenomeWeb News) – Cisbio Bioassays today announced a deal to distribute BellBrook Labs' Transcreener Epigen Methyltransferase assay.

Under the terms of the agreement, the second distribution deal between the companies, Cisbio will offer the assay for epigenetics-based drug discovery studies conducted by pharmaceutical and biotechnology researchers in the US, Europe, and Asia.

Transcreener Epigen Methyltransferase is a universal detection method based on Transcreener AMP/GMP assay technology developed by BellBrook that involves coupling enzymes for detection of methyltransferase reaction products. The products are crucial targets in epigenetics research, the partners said.

Financial and other terms of the deal were not disclosed.

In 2008 Cisbio and BellBrook teamed up to launch HTRF Transcreener ADP, an assay for the high-throughput screening and profiling of kinases.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.